Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
about
Hydroxyurea inhibits the transactivation of the HIV-long-terminal repeat (LTR) promoterHIV-1 Transmission, Replication Fitness and Disease Progression.The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activitiesIndividual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus.A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus.Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infectionSubunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophageApparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V.Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions.The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.Synthesis of virus-specific high-mobility DNA after temperature upshift of SC-1 cells chronically infected with moloney murine leukemia virus mutant ts1.Altering the intracellular environment increases the frequency of tandem repeat deletion during Moloney murine leukemia virus reverse transcription.Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity.Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1.Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.Interrelationship between HIV-1 fitness and mutation rate.Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.
P2860
Q28344235-A80449E7-07AD-4061-9554-3C53B5534F12Q33758570-3A3D3FE4-805B-4627-AB55-AF6CFA075ED9Q33815628-2FE1CB0B-3BF3-4089-9A6D-95DDA42FA3D6Q33838311-74F89023-FD18-4BFF-8C53-701609F14E82Q33873983-00F49EB3-498D-4BC7-A218-521E7EB4BC75Q33906239-2E53355B-713B-4DA8-B6E5-1B85C0BEF852Q34058254-8D122CF2-699F-4A47-BB42-F02D93D9E95BQ34361509-E6153440-AD88-4AEA-AB33-0EAA1219DB7BQ34573897-934FEF95-3555-4D39-B99B-E90EBE1AA388Q35104695-E731413D-4211-48A4-B302-D4590097671DQ36172087-637E9D19-A154-4D22-AA6C-06C385C5AF01Q36727259-EB44CB19-4585-421F-B66D-6C1C27C807B4Q36727282-961CB509-750D-404F-94BF-0A6D0457129AQ37018369-151DEED5-FEFF-45A1-B89B-5377822E97C3Q37093847-B675E532-2053-454E-9388-667C95C51ABFQ37404676-F8D8C7FF-6F76-435B-B761-4EB5CC0CF462Q37452008-762EB5C7-AD7C-4257-84AC-B367970BC814Q37547275-1898F9BE-7365-46D1-94D3-1B30695066B4Q39592409-7D97D1BE-523B-4346-8A82-4B5B88783530Q39595957-BC072CCB-A728-4A0A-AD2A-6ACA6E9B377DQ39651471-045FA76D-2462-455F-B250-1FA6597BB9CDQ39797039-3862F4F6-162D-4547-823F-247C2293C7C3Q40173457-8930DB64-3FC1-46CA-8AE7-B38B2305B975Q40721745-40FF4FA6-79D5-4D6D-8C90-0355F390A6FBQ41862836-0DE8EC38-A0AF-4AA9-BB8F-18CDD583FCEAQ41888126-C1CDE127-3914-4C3F-8F3F-1250C4B1F77DQ42062012-FCFAB124-AA92-4A89-9F92-CBC28E0BA775
P2860
Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Limiting deoxynucleoside triph ...... s type 1 reverse transcriptase
@en
Limiting deoxynucleoside triph ...... type 1 reverse transcriptase.
@nl
type
label
Limiting deoxynucleoside triph ...... s type 1 reverse transcriptase
@en
Limiting deoxynucleoside triph ...... type 1 reverse transcriptase.
@nl
prefLabel
Limiting deoxynucleoside triph ...... s type 1 reverse transcriptase
@en
Limiting deoxynucleoside triph ...... type 1 reverse transcriptase.
@nl
P2860
P1476
Limiting deoxynucleoside triph ...... s type 1 reverse transcriptase
@en
P2093
P2860
P304
P407
P577
1997-11-01T00:00:00Z